Ackermans & Van Haaren Supports MRM Health’s Series B Financing Round of 55 Million Euros

Ackermans & van Haaren supports MRM Health’s Series B financing round of 55 million euros

Dear shareholder, Dear Madam, Dear Sir, Ackermans & van Haaren (AvH) supports the Series B financing round totaling 55 million euros of MRM Health,...

MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline

GHENT, Belgium -- MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round.

MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline - Business Wire

Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval Strategic partnership with Biocodex in biotherapeutics development and manufacturing adds significant non-dilutive funding in addition to the Series B financing Investment fuels expansion of proprietary CORAL ® platform and pipeline (ANSA)

MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline – The Times of Bengal

Business Wire India   Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval Strategic partnership with Biocodex in biotherapeutics development and manufacturing adds significant non-dilutive funding in addition to the Series B financing Investment fuels expansion of proprietary CORAL® platform and pipeline   \MRM Health NV, a clinical-stage biopharmaceuti…

Microbiome play MRM Health NV raises €55m in Series B - European Biotechnology Magazine

Belgian VIB spin-out MRM Health NV is using fresh funds raised in a €55m follow-on financing round to make its microbiome preparation MH002 licensable in an ongoing Phase IIb study for the indication ulcerative colitis. With €55m (US$64m) in Series B financing, The post Microbiome play MRM Health NV raises €55m in Series B appeared first on European Biotechnology Magazine.

Microbiome startup MRM Health nabs €55M Series B to run Phase 2b ulcerative colitis trial

A Belgian startup researching microbiome therapies for I&I diseases and cancer raised a new round of cash that it hopes can get its lead drug into Phase 3 studies. MRM Health said Thursday that it ...